Specific antidotes against direct oral anticoagulants: A comprehensive review of clinical trials data

International Journal of Cardiology

Volumn 214, Issue , 2016, Pages 292-298

  Tummala, Ramyashree ^a   Kavtaradze, Ana ^a   Gupta, Anjan ^b   Ghosh, Raktim Kumar ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

Andexanet alfa; ANNEXA A; ANNEXA R; Antidote; Apixaban; Dabigatran; DOAC; Edoxaban; Idarucizumab; NOAC; Praxbind; Rivaroxaban

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; ANDEXANET ALFA; ANTICOAGULANT AGENT; ANTIDOTE; APIXABAN; CIRAPARANTAG; DABIGATRAN; EDOXABAN; FONDAPARINUX; IDARUCIZUMAB; RIVAROXABAN; WARFARIN; BLOOD CLOTTING FACTOR 10A; MONOCLONAL ANTIBODY; RECOMBINANT PROTEIN;

ANTICOAGULATION; BLEEDING; CLINICAL TRIAL (TOPIC); DEEP VEIN THROMBOSIS; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; HEMODIALYSIS; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW; THROMBOEMBOLISM; THROMBOSIS; TREATMENT RESPONSE; VENOUS THROMBOEMBOLISM; CHEMICALLY INDUCED; HEMORRHAGE; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTICOAGULANTS; ANTIDOTES; CLINICAL TRIALS AS TOPIC; DABIGATRAN; FACTOR XA; HEMORRHAGE; HUMANS; RECOMBINANT PROTEINS;

EID: 84963552939     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2016.03.056     Document Type: Review

References (78)

1. AJ, P. Kirchhof, G.Y. Lip, U. Schotten, I. Savelieva, S. Ernst, and et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC) Eur. Heart J. 31 2010 2369 2429
2. J.J. You, D.E. Singer, P.A. Howard, D.A. Lane, M.H. Eckman, M.C. Fang, and et al. Lip GY antithrombotic therapy for atrial fibrillation: antithrombotic therapy and prevention of thrombosis, 9th ed:American College of Chest Physicians Evidence-Based Clinical Practice Guidelines Chest 141 2012 e531S e575S
3. P.A. Wolf, R.D. Abbott, and W.B. Kannel Atrial fibrillation as an independent risk factor for stroke: the Framingham Study Stroke 22 1991 983 988
4. A. Gómez-Outes, M.L. Suárez-Gea, G. Calvo-Rojas, R. Lecumberri, E. Rocha, C. Pozo-Hernández, and et al. Discovery of anticoagulant drugs: a historical perspective Curr. Drug Discov. Technol. 9 2012 83 104
5. R. Reynolds, and V. Essebag Economic burden of atrial fibrillation: implications for intervention Am. J. Pharm. Benefits 4 2012 58 65
6. F.A. Spencer, C. Emery, D. Lessard, F. Anderson, S. Emani, J. Aragam, and et al. The Worcester Venous Thromboembolism study: a population-based study of the clinical epidemiology of venous thromboembolism J. Gen. Intern. Med. 21 2006 722 727
7. P.P. Dobesh Economic burden of venous thromboembolism in hospitalized patients Pharmacotherapy 29 2009 943 953
8. R.G. Hart, L.A. Pearce, and M.I. Aguilar Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation Ann. Intern. Med. 146 2007 857 867
9. J. Ansell, J. Hirsh, E. Hylek, A. Jacobson, M. Crowther, and G. Palareti Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest 133 2008 160S 198S
10. L. Friberg, N. Hammar, M. Ringh, H. Pettersson, and M. Rosenqvist Stroke prophylaxis in atrial fibrillation: who gets it and who does not? Report from the Stockholm Cohort-study on atrial fibrillation (SCAF-study) Eur. Heart J. 27 2006 1954 1964
11. J. Fareed, D.A. Hoppensteadt, D. Fareed, M. Demir, R. Wahi, M. Clarke, and et al. Survival of heparins, oral anticoagulants, and aspirin after the year 2010 Semin. Thromb. Hemost. 34 2008 58 73
12. A. Gómez-Outes, A.I. Terleira-Fernández, G. Calvo-Rojas, M.L. Suárez-Gea, and E. Vargas-Castrillón Dabigatran, Rivaroxaban, or Apixaban versus Warfarin in Patients with Nonvalvular Atrial Fibrillation: a systematic review and meta-analysis of subgroups Thrombosis 2013 2013 640 723
13. European Medicines Agency Pradaxa-summary of product characteristics http://www.ema.europa.eu/docs/en GB/document library/EPAR - Product Information/human/000829/000829/WC500041059.pdf 2013
14. European Medicines Agency Xarelto-summary of product characteristics http://www.ema.europa.eu/docs/enGB/document library/EPAR - Product Information/human/000944/WC500057108.pdf 2013
15. European Medicines Agency Eliquis-summary of product characteristics http://www.ema.europa.eu/docs/en GB/document library/EPAR - Product Information/human/002148/sWC500107728.pdf 2013
16. J. Fareed, O. Iqbal, J. Cunanan, M. Demir, R. Wahi, M. Clarke, and et al. Changing trends in anti-coagulant therapies. Are heparins and oral anticoagulants challenged? Int. Angiol. 27 2008 176 192
17. S.J. Connolly, M.D. Ezekowitz, S. Yusuf, J. Eikelboom, J. Oldgren, A. Parekh, and et al. RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation N. Engl. J. Med. 361 2009 1139 1151
18. B.N. Beasley, E.F. Unger, and R. Temple Anticoagulant options - why the FDA approved a higher but not a lower dose of dabigatran N. Engl. J. Med. 364 2011 1788 1790
19. M. Katsnelson, R.L. Sacco, and M. Moscucci Progress for stroke prevention with atrial fibrillation: the emergence of alternative oral anticoagulants Circulation 125 2012 1577 1583
20. M.R. Patel, K.W. Mahaffey, J. Garg, G. Pan, D.E. Singer, W. Hacke, and et al. ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation N. Engl. J. Med. 365 2011 883 891
21. S.D. Kristensen, J.Y. Le Heuzey, H. Mavrakis, L. Mont, P.P. Filardi, P. Ponikowski, and et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation∗Developed with the special contribution of the European Heart Rhythm Association Eur. Heart J. 33 2012 2719 2747
22. C.T. January, L.S. Wann, J.S. Alpert, H. Calkins, J.C. Cleveland Jr., J.E. Cigarroa, and et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: areport of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society Circulation 130 2014 2071 2104
23. S. Harder, and J. Graff Novel oral anticoagulants: clinical pharmacology, indications, and practical considerations Eur. J. Clin. Pharmacol. 69 2013 1617 1633
24. C.B. Granger, J.H. Alexander, J.J. McMurray, R.D. Lopes, E.M. Hylek, M. Hanna, and et al. ARISTOTLE committees and investigators. Apixaban versus warfarin in patients with atrial fibrillation N. Engl. J. Med. 365 2011 981 992
25. P. Gallego, V. Roldán, and G.Y. Lip Novel oral anticoagulants in cardiovascular disease J. Cardiovasc. Pharmacol. Ther. 19 2014 34 44
26. R.P. Giugliano, C.T. Ruff, E. Braunwald, S.A. Murphy, S.D. Wiviott, J.L. Halperin, and et al. ENGAGE AF-TIMI 48 investigators. Edoxaban versus warfarin in patients with atrial fibrillation N. Engl. J. Med. 369 2013 2093 2104
27. N.C. Chan, J. Hirsh, J.S. Ginsberg, and J.W. Eikelboom Betrixaban (PRT054021): pharmacology, dose selection, and clinical studies Futur. Cardiol. 10 2014 43 52
28. C.H. Yeh, K. Hogg, and J.I. Weitz Overview of the new oral anticoagulants: opportunities and challenges Arterioscler. Thromb. Vasc. Biol. 35 2015 1056 1065
29. G.A. Soff A new generation of direct oral anticoagulants Arterioscler. Thromb. Vasc. Biol. 32 2012 569 574
30. J.W. Cheng, and G. Barillari Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions J. Clin. Pharm. Ther. 39 2014 118 135
31. S. Antoniou Rivaroxaban for the treatment and prevention of thromboembolic disease J. Pharm. Pharmacol. 67 2015 1119 1132
32. C.V. Pollack Jr. Coagulation assessment with the new generation of oral anticoagulant Emerg. Med. J. 2015 (May 18. pii: emermed-2015-204891)
33. C. Epple, and T. Steiner Acute stroke in patients on new direct oral anticoagulants: how to manage, how to treat? Expert. Opin. Pharmacother. 15 2014 1991 2001
34. J. Stangier, K. Rathgen, H. Stähle, D. Gansser, and W. Roth The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects Br. J. Clin. Pharmacol. 64 2007 292 303
35. J. Van Ryn, L. Baruch, and A. Clemens Interpretation of point-of-care INR results in patients treated with dabigatran Am. J. Med. 125 2012 417 420
36. L. Baruch, and O. Sherman Potential inaccuracy of point-of-care INR in dabigatran-treated patients Ann. Pharmacother. 45 2011 e40
37. J. Van Ryn, J. Stangier, S. Haertter, K.H. Liesenfeld, W. Wienen, M. Feuring, and et al. Dabigatran etexilate - a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity Thromb. Haemost. 103 2010 1116 1127
38. T.L. Lindahl, F. Baghaei, I.F. Blixter, K.M. Gustafsson, L. Stigendal, M. Sten-Linder, and et al. Effects of the oral, direct thrombin inhibitor dabigatran on five common coagulation assays Thromb. Haemost. 105 2011 371 378
39. J. Douxfils, F. Mullier, S. Robert, C. Chatelain, B. Chatelain, and J.M. Dogne Impact of dabigatran on a large panel of routine or specific coagulation assays. Laboratory recommendations for monitoring of dabigatran etexilate Thromb. Haemost. 107 2012 985 997
40. A. Hillarp, F. Baghaei, I. Fagerberg Blixter, K.M. Gustafsson, L. Stigendal, M. Sten-Linder, and et al. Effects of the oral, direct factor Xa inhibitor rivaroxaban on commonly used coagulation assays J. Thromb. Haemost. 9 2011 133 139
41. M.M. Samama, J.L. Martinoli, L. LeFlem, C. Guinet, G. Plu-Bureau, F. Depasse, and et al. Assessment of laboratory assays to measure rivaroxaban - an oral, direct factor Xa inhibitor Thromb. Haemost. 103 2010 815 825
42. D. Kubitza, M. Becka, G. Wensing, B. Voith, and M. Zuehlsdorf Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939 - an oral, direct factor Xa inhibitor - after multiple dosing in healthy male subjects Eur. J. Clin. Pharmacol. 61 2005 873 880
43. C. Frost, J. Wang, S. Nepal, A. Schuster, Y.C. Barrett, R. Mosqueda-Garcia, and et al. Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects Br. J. Clin. Pharmacol. 75 2013 476 487
44. Y.C. Barrett, Z. Wang, C. Frost, and A. Shenker Clinical laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay Thromb. Haemost. 104 2010 1263 1271
45. C.V. Pollack Jr. Coagulation assessment with the new generation of oral anticoagulants Emerg. Med. J. 18 2015 May
46. P. Sardar, S. Chatterjee, C.J. Lavie, J.S. Giri, J. Ghosh, D. Mukherjee, and et al. Risk of major bleeding in different indications for new oral anticoagulants: insights from a meta-analysis of approved dosages from 50 randomized trials Int. J. Cardiol. 179 2015 Jan 20 279 287
47. K. Bouillon, M. Bertrand, G. Maura, P.O. Blotière, P. Ricordeau, and M. Zureik Risk of bleeding and arterial thromboembolism in patients with non-valvular atrial fibrillation either maintained on a vitamin K antagonist or switched to a non-vitamin K-antagonist oral anticoagulant: a retrospective, matched-cohort study Lancet Haematol. 2 2015 e150 e159
48. S. Schulman, C. Kearon, A.K. Kakkar, P. Mismetti, S. Schellong, H. Eriksson, and et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism N. Engl. J. Med. 361 2009 2342 2352
49. S. Schulman, A.K. Kakkar, S.Z. Goldhaber, S.M. Schellong, H. Eriksson, and P. Mismetti Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis Circulation 129 2014 764 772
50. E.I.N.S.T.E.I.N. Investigators, R. Bauersachs, S.D. Berkowitz, B. Brenner, H.R. Buller, H. Decousus, and et al. Oral rivaroxaban for symptomatic venous thromboembolism N. Engl. J. Med. 363 2010 2499 2510
51. EINSTEIN-PE Investigators, H.R. Büller, M.H. Prins, A.W. Lensin, H. Decousus, B.F. Jacobson, and et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism N. Engl. J. Med. 366 2012 1287 1297
52. A. Majeed, H.-G. Hwang, M. Brueckmann, and et al. Management and outcomes of major bleeding on dabigatran or warfarin Blood 120 2012
53. S.H. Ibbotson, P.J. Grant, R. Kerry, and et al. The influence of infusions of 1-desamino-8-D-arginine vasopressin (DDAVP) in vivo on the anticoagulant effect of recombinant hirudin (CGP39393) in vitro Thromb. Haemost. 65 1991 64 66
54. M. Elg, S. Carlsson, and D. Gustafsson Effects of activated prothrombin complex concentrate or recombinant factor VIIa on bleeding time and thrombus formation during anticoagulation with a direct thrombin inhibitor Thromb. Res. 101 2001 145 157
55. R. Marlu, E. Hodaj, and A. Paris Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban. A randomized crossover ex vivo study in healthy volunteers Thromb. Haemost. 108 2012 217 224
56. T.L. Khoo, C. Weatherburn, and G. Kershaw The use of FEIBA in the correction of coagulation abnormalities induced by dabigatran Int. J. Lab. Hematol. 35 2013 222 224
57. E.S. Eerenberg, P.W. Kamphuisen, and M.K. Sijpkens Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects Circulation 124 2011 1573 1579
58. A. Lillo-Le Louet, M. Wolf, and L. Soufir Life-threatening bleeding in four patients with an unusual excessive response to dabigatran: implications for emergency surgery and resuscitation Thromb. Haemost. 108 2012 583 585
59. M. Wolzt, M. Levi, and T.C. Sarich Effect of recombinant factor VIIa on melagatran-induced inhibition of thrombin generation and platelet activation in healthy volunteers Thromb. Haemost. 91 2004 1090 1096
60. T.E. Warkentin, P. Margetts, and S. Connolly Recombinant factor VIIa (rFVIIa) and hemodialysis to manage massive dabigatran-associated postcardiac surgery bleeding Blood 119 2012 2172 2174
61. J. Stangier, K. Rathgen, and H. Stahle Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study Clin. Pharmacokinet. 49 2010 259 268
62. M.R. Wanek, E.T. Horn, and S. Elapavaluru Safe use of hemodialysis for dabigatran removal before cardiac surgery Ann. Pharmacother. 46 2012 e21
63. J. van Ryn, J. Stangier, S. Haertter, K.H. Liesenfeld, W. Wienen, M. Feuring, and et al. Dabigatran etexilate-a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity Thromb. Haemost. 103 2010 1116 1127
64. F. Schiele, J. van Ryn, and K. Canada A specific antidote for dabigatran: functional and structural characterisation Blood 121 2013 3554 3562
65. M. Honickel, O. Grottke, and J. van Ryn Use of a specific antidote to dabigatran (idarucizumab) reduces blood loss and mortality in dabigatran-induced and trauma-induced bleeding in pigs Crit. Care 18 Suppl. 1 2014 99
66. J. van Ryn, T. Litzenburger, and J. Schurer Reversal of anticoagulant activity of dabigatran and dabigatran-induced bleeding in rats by a specific antidote (antibody fragment) Circulation 126 2012 A9928
67. Stephan Glund, Joachim Stangier, Michael Schmohl, Dietmar Gansser, Stephen Norris, Joanne van Ryn, and et al. Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trial Lancet 386 2015 680 690
68. Charles V. Pollack Jr., Paul A. Reilly, John Eikelboom, Stephan Glund, Peter Verhamme, and Richard A. Bernstein Idarucizumab for dabigatran reversal. RE-VERSE AD trial N. Engl. J. Med. 373 2015 511 520
69. PRAXBIND- idarucizumab injection. Boehringer Ingelheim Pharmaceuticals, Inc. https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid
70. G. Lu, F.R. DeGuzman, and S.J. Hollenbach A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa Nat. Med. 19 2013 446 451
71. M. Crowther, G. Lu, and P.B. Conley Reversal of factor Xa inhibitors-induced anticoagulation in healthy subjects by and exanet alfa Crit. Care Med. 42 2014 A1469-A1469
72. M.A. Crowther, G. Levy, and G. Lu A phase 2 randomized, double-blind, placebo-controlled trial demonstrating reversal of edoxaban-induced anticoagulation in healthy subjects by andexanet alfa (PRT064445), a universal antidote for factor Xa (fXa) inhibitors Presented at the 56th annual meeting of the American Society of Hematology, San Francisco December 6-9, 2014
73. M.A. Crowther, V. Mathur, and M. Kitt A phase 2 randomized, double-blind, placebo-controlled trial demonstrating reversal of rivaroxaban-induced anticoagulation in healthy subjects by andexanet alfa (PRT064445), an antidote for Fxa inhibitors Presented at the 55th annual meeting of the American Society of Hematology, New Orleans December 7-10, 2013
74. D.M. Siegal, J.T. Curnutte, S.J. Connolly, G. Lu, P.B. Conley, B.L. Wiens, and et al. Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity N. Engl. J. Med. 373 25 2015 Dec 17 2413 2424
75. B. Laulicht, S. Bakhru, X. Jiang, and et al. Antidote for new oral anticoagulants: mechanism of action and binding specificity of PER977 Presented at the 24th Congress of the International Society on Thrombosis and Haemostasis, Amsterdam June 29-July 4, 2013
76. B. Laulicht, S. Bakhru, C. Lee, and et al. Small molecule antidote for anticoagulants Circulation 126 2012 A11395
77. C.T. Ruff, R.P. Giugliano, E. Braunwald, D.A. Morrow, S.A. Murphy, J.F. Kuder, and et al. Association between edoxaban dose, concentration, anti-factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial Lancet 385 9984 2015 Jun 6 2288 2295
78. J.E1. Ansell, S.H. Bakhru, B.E. Laulicht, S.S. Steiner, M. Grosso, K. Brown, and et al. Use of PER977 to reverse the anticoagulant effect of edoxaban N. Engl. J. Med. 371 22 Nov 27, 2014 2141 2142